MedPath

Monogram Technologies Receives FDA Request for Additional Information on mBôs TKA System

• Monogram Technologies received an Additional Information Request (AIR) from the FDA for its mBôs TKA System, requiring a response within 180 days. • The company plans to conduct clinical trials in India to gather necessary data for the FDA submission, aiming for regulatory clearance in early Q1 2025. • Monogram is pursuing a dual-track approach, addressing the AIR for the semi-active system while advancing its active modality with OUS clinical data. • A recently closed $13 million public offering will support Monogram's strategic objectives and the continued development of its orthopedic robotics system.

Monogram Technologies Inc. (NASDAQ:MGRM) has announced it received an Additional Information Request (AIR) from the U.S. Food and Drug Administration (FDA) regarding its 510(k) premarket filing for the mBôs TKA System. The company has 180 days to respond to the AIR, or the application will be considered withdrawn. This development impacts the timeline for FDA clearance of the robotic surgical system designed for total knee arthroplasty.

FDA Response and Company Strategy

The AIR was issued on September 30, 2024, following the initial administrative review of the application submitted on July 19, 2024. Monogram Technologies plans to conduct clinical trials to generate the required information, with a focus on gathering data efficiently. CEO Ben Sexson stated that the response provides increased clarity for Monogram's path toward clearance and commercialization.
Monogram is adopting a dual-track approach. While addressing the AIR for its semi-active system, the company will also pursue a submission for its active modality using clinical data obtained outside the United States (OUS). This parallel strategy aims to expedite the overall clearance process.

Clinical Trials and Regulatory Milestones

Upcoming milestones for Monogram include obtaining regulatory clearance to conduct clinical trials in India with strategic partner Shalby Hospitals, expected in early Q1 2025. These trials are projected to include 92 total knee replacement procedures, with a 3-month clinical follow-up. The company also plans to conduct OUS live-patient surgery trials and submit the resulting clinical trial data to the FDA.

Financial Position and Market Interest

Monogram Technologies recently closed an upsized and oversubscribed $13 million public offering. This financial boost will support the company's strategic objectives and the continued development of its orthopedic robotics system. According to Monogram, there is growing surgeon support and market interest in the mBôs TKA System, particularly the hands-free, fully active version, which the company believes could be a game-changing advancement for the industry.

About the mBôs TKA System

The mBôs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of Monogram's FDA-cleared mPress press-fit implants. The goal is to achieve well-balanced, better-fitting, and bone-sparing knee replacements. Monogram intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other instrumentation necessary for reconstructive joint replacement procedures.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Monogram Technologies Advances mBôs TKA System Toward FDA Clearance

Monogram Technologies anticipates addressing FDA concerns regarding its mBôs TKA System without requiring clinical data, potentially accelerating the path to market.
The company plans to submit a comprehensive response to the FDA's Additional Information Request (AIR) in the first quarter of 2025.

J&J Seeks FDA Approval for Subcutaneous TREMFYA® Induction in Ulcerative Colitis

Johnson & Johnson has submitted an application to the FDA for a subcutaneous induction regimen of TREMFYA® (guselkumab) for ulcerative colitis.
The application is based on the Phase 3 ASTRO study, which met its primary endpoint of clinical remission at Week 12 with statistical significance.

Tonix Pharmaceuticals Seeks FDA Approval for TNX-102 SL in Fibromyalgia

Tonix Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for TNX-102 SL, targeting sleep and pain relief in fibromyalgia patients.
Phase 3 trials demonstrated that TNX-102 SL significantly reduced daily pain and improved sleep quality compared to placebo in fibromyalgia patients.

Tonix Pharmaceuticals Bolsters Leadership as TNX-102 SL Awaits FDA Decision for Fibromyalgia

Tonix Pharmaceuticals has appointed Bradley Raudabaugh as VP of Marketing and Errol Gould as VP of Medical Affairs to support the potential launch of TNX-102 SL.
The FDA is expected to decide on the acceptance of the New Drug Application (NDA) for TNX-102 SL in December 2024, with a potential approval decision in 2025.

Appili Therapeutics Receives Positive FDA Feedback on ATI-1801 Development for NDA Submission

Appili Therapeutics announced that the FDA has provided positive feedback on its development strategy for ATI-1801, a topical antiparasitic product.
The FDA's feedback aligns with the requirements for a New Drug Application (NDA) submission, marking a significant milestone for the drug's development.

iRhythm Technologies Receives FDA Clearance for Zio AT Design Updates, Stock Surges

iRhythm Technologies (IRTC) secured FDA 510(k) clearance for design updates to its Zio AT cardiac monitoring device, addressing prior regulatory concerns.
The approval marks a significant step in iRhythm's ongoing efforts to meet FDA compliance and enhance the quality and safety of its Zio AT system.

SI-BONE's iFuse TORQ TNT Implant System Receives FDA Clearance for Pelvic Fragility Fractures

SI-BONE's iFuse TORQ TNT implant system has received FDA 510(k) clearance, offering a novel solution for pelvic fragility fractures.
The TNT system is designed to address the specific anatomical and bone mineral density needs of the sacrum and ilium, potentially improving treatment outcomes.

FDA Rejects Lykos Therapeutics' Midomafetamine for PTSD, Demands Additional Phase 3 Trial

The FDA issued a complete response letter for Lykos Therapeutics' NDA for midomafetamine capsules, intended to treat PTSD in adults, citing insufficient data.
Lykos plans to request a meeting with the FDA to discuss the agency's recommendations and seek reconsideration of the decision regarding midomafetamine.

Tonix Pharmaceuticals' Tonmya™ Receives Conditional FDA Acceptance for Fibromyalgia Treatment

Tonix Pharmaceuticals' TNX-102 SL, conditionally named Tonmya™, has received FDA acceptance as a trade name for fibromyalgia management.
Two positive Phase 3 trials demonstrated Tonmya's potential as a novel, first-line treatment option for fibromyalgia, affecting millions in the U.S.

Izotropic Files Pre-Submission Application With U.S. FDA for Breast CT Imaging System

Izotropic Corporation has taken a significant step towards market approval for its Breast CT Imaging System by filing a Pre-Submission Application with the U.S. FDA. This move marks a pivotal moment in the company's journey to revolutionize breast cancer imaging, aiming to provide a less painful and more efficient diagnostic tool compared to traditional mammography.

Reference News

[1]
Monogram Technologies Receives FDA Response for mBôs TKA System - Stock Titan
stocktitan.net · Oct 2, 2024

Monogram Technologies received an FDA Additional Information Request for its mBôs TKA System, with 180 days to respond. ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy